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Introduction: Blood C-reactive protein (CRP) and fecal calprotectin levels are routinely
measured as surrogate markers of disease activity in Inflammatory Bowel Disease
(IBD), but often do not correlate well with the degree of mucosal inflammation in
the intestine as established by endoscopy. Therefore, novel predictive biomarkers are
urgently needed that better reflect mucosal disease activity in IBD. The aim of this
study was to identify a combination of serum inflammatory biomarkers predictive for
endoscopic disease activity.
Methods: Serum concentrations of 10 inflammatory biomarkers were analyzed in 118
IBD patients [64 Crohn’s disease (CD), 54 ulcerative colitis (UC)] and 20 healthy controls.
In a subset of 71 IBD patients, endoscopic disease activity was established. Non-
parametric ROC estimation with bootstrap inference was used to establish the best
combination of inflammatory biomarkers predicting endoscopic disease activity.
Results: Six (6) inflammatory biomarkers (serum amyloid A (SAA), Eotaxin-1, IL-6,
IL-8, IL-17A, and TNF-α) showed better prediction of IBD disease activity than routine
measures (CRP, fecal calprotectin and HBI/SCCAI scores). The best combination of
predictive inflammatory biomarkers consisted of serum SAA, IL-6, IL-8, and Eotaxin-
1, showing an optimism-adjusted area under the ROC (AuROC) curve of 0.84 (95% CI:
0.73–0.94, P< 0.0001), which predicted significantly better (P= 0.002) than serum CRP
levels with an AuROC of 0.57 (95% CI: 0.43–0.72, P = 0.32).
Conclusion: The combination of SAA, IL-6, IL-8, and Eotaxin-1 reliably predicts
endoscopic disease activity in IBD and might be valuable for monitoring disease activity
and management of the disease.
Keywords: Inflammatory Bowel Disease (IBD), inflammatory biomarkers, endoscopy, inflammation, disease
activity
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INTRODUCTION
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic
idiopathic inflammatory bowel diseases (IBD), characterized by
an inappropriate and uncontrolled immune response, stimulated
by the gut microbiome in a genetically susceptible host (1).
Typically, patients with IBD follow a disease course consisting
of alternating exacerbations and periods of remission (2). In
IBD, the extent of inflammatory disease activity is preferably
established by endoscopy, that is translated to validated scoring
systems, such as the Mayo endoscopic subscore for UC and
the Simple Endoscopic Score for CD (SES-CD) (3, 4). Frequent
monitoring of IBD disease activity is crucially important, since
long-lasting subclinical disease activity is known to increase the
risk of future surgical interventions and hospitalization and to
decrease patients’ quality of life and economic participation (5–
8). Endoscopic examination is still the most reliable approach
for diagnosing the presence and extent of IBD disease activity
(9). This procedure, however, has several disadvantages, such as
a high patient burden, but also risks of serious complications,
like bowel perforation or bleeding. In addition, it is costly
and time-consuming. Alternatives for endoscopy are therefore
urgently needed.
Non-endoscopic disease indices, such as the Crohn’s Disease
Activity Index (CDAI) or Harvey Bradshaw Index (HBI) for
CD and the Simple Clinical Colitis Activity Index (SCCAI) for
UC, fail to correlate well with endoscopically-proven intestinal
inflammation (10–13). Biomarkers for endoscopic disease
activity have also been explored and are becoming increasingly
important to predict the level of mucosal inflammation in
IBD. Fecal calprotectin (FC) and serum C-reactive protein
(CRP) levels are now widely used and considered predictive
markers for the degree of inflammation, but also show
inconsistent correlation with mucosal inflammation when
compared to endoscopy (14–16). This illustrates the need
for better diagnostic measures for IBD exacerbations that
preferably can also be applied to patients with subclinical disease
activity (17).
Cytokines play a pivotal role in the pathogenesis of IBD,
controlling intestinal inflammation and disease activity, and
might be better predictive markers for disease activity than
FC and CRP (18–20). In many diseases, combinations of
inflammatory cytokines have been shown to be predictive for
inflammatory state and are therewith adequate biomarkers for
non-invasive disease activity monitoring (21). Recently, we
showed that for CD a positive correlation exists between multiple
Th1- and Th17-associated serum cytokines and fecal calprotectin
levels (22). Although no endoscopic results were available for
that patient cohort, it demonstrated the proof of principle and
value of selected Th1- and Th17-associated serum cytokines for
measuring inflammation in IBD. As a next step, we aimed to
evaluate the potential of a combined set of such cytokines to
predict endoscopic disease activity, as one single biomarker will
be unlikely to accurately predict the mucosal status in IBD.
Therefore, a limited set of 10 candidate inflammatory biomarkers
(C-reactive protein (CRP), serum amyloid A (SAA), IFN-γ,
TNF-α, IL-6, IL-8, IL-10, IL-17A, Eotaxin-1, and Eotaxin-3) was
selected based on results from the aforementioned pilot-study
and available literature (18, 20–22).
In the present study, we investigated a selection of 10
inflammatory biomarkers involved in IBD and their association
to inflammatory disease activity as evaluated by endoscopic
examination. Correlations between individual biomarkers and
endoscopic disease activity were analyzed and used to compose
an accurate prediction tool for the level of endoscopic disease
activity, based on a subset of these biomarkers. Finally, we
compared the predictive accuracy of this panel of biomarkers
with commonly applied measures of disease activity, such as
clinical indices (HBI/SCCAI), serum CRP, and FC levels.
MATERIALS AND METHODS
Study Population
This cohort study included patients from the database of the IBD
center of the University Medical Center Groningen (UMCG).
Serum samples from 118 IBD patients, either CD (n = 64) or
UC (n = 54) were collected. At the moment serum samples
were obtained, all patients had an indication for starting new
biological therapy. Indications to initiate biological therapy were
primarily based on increased endoscopic disease activity, though
few (CD) patients had fistulizing disease as therapy indication.
Inclusion criteria for this study were: age ≥ 18 years and an
established diagnosis of IBD existing for at least 1 year. Diagnosis
was based on clinical, endoscopic and histological criteria (23).
Clinically relevant data were retrieved from the patients’ medical
records: age, gender, body-mass index (BMI), smoking status,
Montreal classification, maintenance medication (mesalamine,
thiopurines, methotrexate, TNF-antagonists), disease duration,
previous anti-TNF therapy and surgical history. Clinical disease
activity was recorded by scoring the Harvey Bradshaw Index
(HBI) for CD and the Simple Clinical Colitis Activity Index
(SCCAI) for UC (24, 25).
Ethical Considerations
Serum samples were obtained after patients gave written
informed consent (study approved by the Institutional Review
Board [IRB] of the UMCG registered as no. 08/338). In
addition, serum samples of 20 healthy controls were included
for comparison. These serum samples were retrieved from
an UMCG biobank containing pre-donation samples of living
kidney donors (PSI-UMCG [IRB no. 08/279]). This study
has been performed in accordance with the principles of the
Declaration of Helsinki (2013).
Laboratory Measurements
Serum samples for measurements of routine diagnostic
laboratory parameters, including hemoglobin levels, C-reactive
protein (CRP) levels, erythrocyte sedimentation rate (ESR),
white blood cell count (WBC) and thrombocyte counts, were
obtained simultaneously with the serum samples collected
for measurements of detected inflammatory biomarkers. At
the same time-point, fecal calprotectin levels were quantified
by enzyme-linked immunosorbent assays (ELISA) (Bühlmann
Laboratories AG, Switzerland) in a subgroup of patients (n= 25).
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Endoscopic Disease Activity
Baseline endoscopy investigation was performed in a subset of
71 IBD patients (CD, n = 36; UC, n = 35) within 3 months
prior to serum sample collection (median (IQR) interval: 31
[19–60] days). Endoscopic disease activity was graded based
on available endoscopic images and endoscopy reports written
by certified gastroenterologists from our university hospital
who were not involved in the study. Disease activity was
scored according to the validated Simplified Endoscopic Score
for CD (SES-CD) and Mayo endoscopic subscore for UC
(3, 4). To calculate the SES-CD, 5 different bowel segments
were scored and defined as follows: ileum (excluding the
ileocecal valve or ileocolonic anastomosis), ascending colon
(including ileocecal valve, cecum, and ascending colon until the
hepatic flexure), transverse colon (between hepatic and splenic
flexures), descending colon (from splenic flexure to rectosigmoid
junction) and rectum. All 5 segments were evaluated for 4
different endoscopic variables scored from 0 to 3: size of
ulcers, ulcerated surface, affected surface, and the presence
of narrowings. Ultimately, SES-CD scores were defined as
previously described: endoscopic remission 0–3 points (category
0), mild disease activity 4–10 points (category 1), moderate
disease activity 11–19 points (category 2) and severe disease
activity ≥20 points (category 3) (26). For UC, the Mayo
endoscopic subscore for endoscopic disease activity was obtained
from endoscopy reports written by certified gastroenterologists.
Here, Mayo 0 was defined as endoscopic remission (normal
mucosa), Mayo 1 as mild disease activity (erythema, decreased
vascular pattern, mild friability), Mayo 2 as moderate disease
activity (marked erythema, lack of vascular pattern, friability,
erosions) and Mayo 3 as severe disease activity (spontaneous
bleeding and ulceration). For the purpose of analysis, categories
from both endoscopy scores of CD (SES-CD) and UC (Mayo
endoscopic subscore) were merged on categorical level of
mucosal damage (0–3) to finally create an IBD composite
endoscopy score (27).
Measurement of Inflammatory Biomarkers
A selection of 10 inflammatory biomarkers were measured based
on a previously performed study and available literature (22).
In short, serum samples from all subjects were collected and
stored in 1mL aliquots at −80◦C. After thawing and prior to
analysis, samples were centrifuged for 3min at 2,000 g to remove
remaining debris. Measurement of serum levels of C-reactive
protein (CRP), serum amyloid A (SAA), IFN-γ, TNF-α, IL-6,
IL-8, IL-10, IL-17A, Eotaxin-1, and Eotaxin-3 was implemented
using a customized electrochemiluminescence (ECL) multiplex
assay (Meso Scale Discovery (MSD R©), Meso Scale Diagnostics,
Rockville, MD). ECL signals were fitted to a 4-parameter logistic
model with 1/y2 weighting, ensuring a broad and dynamic range
of molecule detection. Serum concentrations of all detected
molecules were determined by using calibration curves to
which the ECL signals were back-fitted. Final concentrations
were calculated using the MSD Discovery Workbench analysis
software R©. Of all detected biomarker concentrations, 94.0% of
values were within the detection range and remaining values
(6.0%) were excluded from further analysis.
Statistical Analysis
Baseline demographic and clinical characteristics were presented
as means ± standards errors (SEM) or proportions with
corresponding percentages (n, %). Serum concentrations
of inflammatory biomarkers were presented as median
± interquartile ranges (IQR). Assessment of normality of
continuous variables was performed using normal Q-Q plots.
Continuous variables were compared using Student’s t-tests
or Mann-Whitney U-tests according to normality. Categorical
variables were compared using chi-square tests or Fisher’s exact
test, as appropriate. All consecutive analyses were performed in
the subset of 71 IBD patients with available endoscopic results
within 3 months prior to serum analysis. Simple correlations
between inflammatory biomarkers and measures of disease
activity were established using the non-parametric Spearman’s
correlation coefficient (ρ). To evaluate predictive performance of
all detected inflammatory biomarkers regarding composite IBD
endoscopic disease activity, receiver operating characteristics
(ROC) curves were established with associated areas under
the ROC curve (AuROCs) as overall measure of fit. ROC
curves and associated AuROCs were established using the non-
parametric, tie-corrected trapezoidal approximation method.
Two correlated areas under the ROC curve were compared
with each other using a non-parametric approach based on
properties from generalized U-statistics to estimate a covariance
matrix (28). Optimal thresholds for the most promising serum
inflammatory biomarkers (serum amyloid A (SAA), Eotaxin-1,
IL-6, IL-8, IL-17A, and TNF-α) were determined by equally
maximizing sensitivity and specificity to compute the Youden’s
index (J statistic). Optimal thresholds or cut-off points (c) were
established by selecting the highest Youden’s index, defined as:
J = maxc {sensitivity (c)+ specificity (c)− 1}
Combinations of classifiers were empirically tested for their
predictive performance using a non-parametric ROC estimation
of combined predicted probabilities (derived from multivariable
logistic regression) with bootstrap inference. Data were analyzed
using SPSS Statistics 23.0 software package (SPSS Inc., Chicago,
ILL, USA) and STATA software (version 15.0, Stata Corp, College
Station, Texas, USA; commands used: “roctab,” “roccomp,” and
“rocreg”) and visualized using GraphPad Prism version 6.0
(La Jolla, CA, USA). In case of multiple testing, Bonferroni
corrections were applied. Two-tailed P ≤ 0.05 were considered
as statistically significant.
Internal Validation
Because all biomarker performances were tested on the same
dataset, AuROCs and Youden’s indices as overall measures of
predictive performance could potentially be overestimated due
to the correlated nature of the data. To adjust for this potential
bias, a bootstrap resampling procedure using 20,000 replicates
was performed as internal validation and to obtain standard
errors (SE) and confidence intervals (CI) for the AuROCs of best
biomarker combinations.
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RESULTS
Study Cohort Characteristics
Baseline demographic and clinical characteristics of
the total study population (n = 138) are presented in
Supplementary Table 1. The IBD study cohort consisted of
118 patients, of which 64 patients with CD and 54 patients
with UC. For comparison, 20 healthy individuals (healthy
controls, HC) were included in the study. IBD patients had
a significantly lower mean age (CD: 43.8 ± 1.8 years; UC:
47.0 ± 2.0 years) as compared to healthy controls (56.1 ± 2.2
years), while no significant gender differences were observed
[CD: 39 females (60.9%); UC: 26 females (48.1%); HC: 12
females (60.0%)]. Further differences between CD and UC
patients were largely related to disease-specific characteristics
(Supplementary Table 1).
For all IBD patients, different measures of disease activity
were recorded and compared between CD and UC patients
(Supplementary Table 2). As clinical disease activity index,
the Harvey Bradshaw Index (HBI) was calculated for CD
patients, whereas the Simple Clinical Colitis Activity Index
(SCCAI) was recorded for UC patients. Median HBI score
was 8 points (IQR: 6–11) and median SCCAI score was
6 points (IQR: 4–8). Serum CRP levels and ESR (mm/h)
were significantly higher in CD patients as compared to UC
patients, whereas the latter group showed significantly higher
levels of FC. Considering endoscopic disease activity, more
CD patients fell into either remission (0–3 points) or mild
(4–10 points) disease categories (CD: 47.2%; UC: 20.0%),
whereas the majority of UC patients belonged to moderate
(11–19 points) and severe (≥20 points) disease categories
(UC: 80.0%; CD: 52.8%).
Analysis of 10 Inflammatory Biomarkers in
118 IBD Patients and 20 Healthy Controls
Serum concentrations of 10 selected serum inflammatory
biomarkers in IBD patients and healthy controls are presented
in Table 1. In CD patients, four (4) out of 10 inflammatory
biomarkers (CRP, SAA, IL-6, and IL-17A) showed significantly
increased concentrations as compared to healthy controls (HC).
Also, four (4) out of 10 biomarkers were significantly increased
in UC compared to HC (SAA, IL-8, IL-10, and IL-17A),
where SAA and IL-17A overlapped with CD. In addition,
the levels of 6 inflammatory biomarkers were significantly
different between CD and UC patients: levels of CRP, IFN-
γ, and IL-6 were significantly higher in CD, while IL-
8, IL-10, and Eotaxin-1 levels were significantly higher in
UC (Figure 1). No significant differences were observed for
serum levels of TNF-α and Eotaxin-3 between CD, UC,
and HC.
Correlations of Inflammatory Biomarkers
With Endoscopic Disease Activity in IBD
Endoscopic examination of 71 (CD: n = 36 and UC: n =
35) of the 118 IBD patients was available and this subgroup
was used to analyze correlations between the individual serum
biomarkers and clinical (HBI/SCCAI), biochemical (CRP, fecal
TABLE 1 | Median (IQR) of baseline serum concentrations of all detected
molecules in CD (n = 64) and UC (n = 54) patients as compared to healthy
controls (HC) (n = 20).
Detected
molecules







































































Data are presented as median (IQR).
Differences between groups were tested using Kruskal-Wallis tests. P < 0.05 were
considered statistically significant (Bonferroni-adjusted, indicated in bold).
calprotectin) and endoscopic (CD: SES-CD score, UC: Mayo
score, IBD: composite endoscopy score) measures of disease
activity using Spearman’s rank correlation coefficients (ρ).
Baseline demographic and clinical characteristics of this subset
of patients (n = 71) are presented in Supplementary Table 3.
Correlations between serum biomarkers and measures of disease
activity are presented in a correlation matrix (Table 2). The SES-
CD score positively correlated with serum amyloid A (SAA) (ρ
= 0.410, P < 0.05), closely followed by IFN-γ (ρ = 0.383, P <
0.05), IL-8 (ρ = 0.359, P < 0.05) and IL-17A (ρ = 0.352, P <
0.05), while the Mayo endoscopic subscore (for UC) correlated
only significantly with serum levels of IL-6 (ρ = 0.356, P< 0.05).
An IBD composite endoscopy score was created by merging
both endoscopy scores of CD (SES-CD) and UC (Mayo) on
categorical level of disease activity (0, 1, 2, or 3). Using this
composite IBD endoscopy score (see Supplementary Table 2; n
= 71), significant correlations were observed for Eotaxin-1 (ρ =
0.316, P < 0.01), IL-8 (ρ = 0.295, P < 0.05) and SAA (ρ = 0.288,
P < 0.05) (Supplementary Figure 1). Furthermore, routinely-
measured CRP levels (mg/l) correlated significantly withmultiple
biomarkers analyzed by the ECL multiplex assay (CRP, SAA,
IL-6, IFN-γ, and TNF-α). In contrast, fecal calprotectin (FC)
levels (n = 25) did not show significant correlations with any
of the detected inflammatory biomarkers. Similarly, clinical
disease indices only showed a significant correlation with serum
IL-6 levels (ρ = 0.349, P < 0.01), whereas the remaining
inflammatory biomarkers did not correlate with either HBI or
SCCAI scores.
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FIGURE 1 | Serum levels of selected inflammatory biomarkers in Crohn’s disease (CD) (n = 64) and ulcerative colitis (UC) (n = 54) patients and healthy controls (HC)
(n = 20). (A) Serum CRP levels (mg/l) are significantly increased in CD as compared to UC and healthy controls. (B) Serum SAA levels (mg/l) are significantly increased
in IBD as compared to healthy controls. (C) Serum IFN-γ levels (pg/ml) are significantly more elevated in CD as in UC. (D) Serum IL-6 levels (pg/ml) are significantly
increased in CD as compared to UC and healthy controls. (E) Serum IL-8 levels (pg/ml) are specifically more elevated in UC as compared to CD and HC. (F) Serum
IL-10 levels (pg/ml) are also significantly increased in UC as compared to CD or HC. (G) Serum IL-17A levels (pg/ml) are strongly significantly increased in both CD and
UC as compared to HC. (H) Serum Eotaxin-1 levels (ng/ml) are significantly elevated in UC as compared to CD, but comparable with that of HC. *P < 0.05 were
considered statistically significant. **P < 0.01. ***P < 0.001.
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TABLE 2 | Correlations between serum levels of individual biomarkers with
endoscopic (SES-CD, Mayo score and composite IBD endoscopy score),














CRP (mg/l) 0.155 −0.053 −0.067 0.101 0.871** 0.022
SAA (mg/l) 0.410* 0.208 0.288* 0.006 0.605** 0.064
IFN-γ (pg/ml) 0.383* 0.119 0.048 0.034 0.325** −0.221
TNF-α (pg/ml) 0.021 0.183 0.175 −0.048 0.298** −0.089
IL-6 (pg/ml) 0.164 0.356* 0.129 0.349** 0.450** 0.079
IL-8 (pg/ml) 0.359* 0.118 0.295* −0.076 0.002 0.006
IL-10 (pg/ml) 0.097 −0.023 0.127 0.172 −0.020 0.189
IL-17A (pg/ml) 0.352* −0.073 0.202 −0.125 0.185 0.113
Eotaxin-1
(ng/ml)
0.212 0.144 0.316** 0.060 −0.121 0.053
Eotaxin-3
(pg/ml)
−0.205 −0.217 −0.110 −0.059 −0.098 0.028
Correlation matrix showing Spearman’s rank correlation coefficients (ρ) for associations
between all detected molecules and clinical, biochemical and endoscopic measures
of disease activity. *P < 0.05 were considered statistically significant. **P < 0.01.
Significances are indicated in bold.
Predicting Endoscopic Disease Activity
Using Inflammatory Biomarkers
To test the predictive performances of selected inflammatory
biomarkers, distributions of serum concentrations of all
biomarkers were compared between IBD patients with binary
categorized, composite IBD endoscopic disease activity:
remission (0) or mild (1) endoscopic disease activity vs.
moderate (2) or severe (3) endoscopic disease activity
(Supplementary Table 4). Subsequently, subgroup analyses
were performed for CD and UC patients separately, which
can be found in Supplementary Table 5 and are visualized in
Supplementary Figures 2–5.
Using the composite IBD endoscopy score, patients
with high endoscopic disease activity [either moderate (2)
or severe (3)] demonstrated significantly elevated serum
concentrations of Eotaxin-1, SAA, TNF-α, IL-6, IL-8, and
IL-17A as compared to patients with low endoscopic disease
activity [either remission (0) or mild (1)] (Figure 2). In the
CD subgroup, using the binary ordered SES-CD, significantly
increased concentrations of SAA, IFN-γ, IL-6, and IL-17A
were observed in patients with high endoscopic disease activity
(Supplementary Table 5; Supplementary Figure 2). In UC,
using the binary Mayo endoscopic subscore categories, serum
concentrations of IL-6, TNF-α, and Eotaxin-1 were significantly
increased in moderate-to-severe disease activity as compared
to remission or mild disease activity (Supplementary Table 5;
Supplementary Figure 4).
To evaluate their predictive accuracies with respect to
endoscopically active disease, receiver operating characteristics
(ROC) curves were established (Figure 3). In the ROC analysis,
serum levels of Eotaxin-1 (pg/ml) and SAA (mg/l) presented
the best discriminative capacity regarding binary ordered,
composite IBD endoscopic disease activity (area under the
receiver operating characteristics curve (AuROC) 0.75 (SE: 0.06,
95% CI: 0.62–0.87, P< 0.001) for both serum Eotaxin-1 and SAA
levels) (Table 3). Serum levels of IL-17A, IL-8, IL-6, and TNF-α
were of subordinate, but still reasonable discriminative value.
Best Combinations of Inflammatory
Biomarkers to Predict Endoscopic Disease
Activity
To achieve the best discrimination between remission (0) or mild
(1) vs. moderate (2) or severe (3) endoscopic disease activity,
multiple combinations of detected inflammatory biomarkers
were empirically investigated for their predictive accuracy.
Ultimately, for the composite IBD endoscopy score, the
best predictive combination of inflammatory biomarkers was
represented by the assembly of serum levels of SAA, IL-6, IL-8,
and Eotaxin-1, showing an AuROC of 0.84 (SE: 0.05, 95% CI:
0.73–0.94, P < 0.0001, n= 64) (Figure 4A). In this combination,
SAA could be replaced by serum CRP levels without losing
predictive accuracy (correlation between CRP and SAA: ρ
= 0.663, P < 0.01) (Supplementary Figure 6). Applying the
algorithm for comparison of correlated ROC curves, the AuROC
for this combination of biomarkers was significantly better as
compared to that of serum CRP levels (P = 0.002), whereas
no statistical significance emerged when compared to fecal
calprotectin levels or the clinical disease scores (HBI/SCCAI) (P
= 0.313 and P = 0.073, respectively). Fecal calprotectin levels
closest to the date of endoscopy were incorporated into this
analysis (n= 25, all within 3 months, median (IQR) time interval
39 [25–55] days). Serum CRP levels had an AuROC of 0.57 (SE:
0.07, 95% CI: 0.43–0.72, P = 0.32), fecal calprotectin (FC) levels
0.66 (n = 25, SE: 0.12, 95% CI: 0.44–0.90, P = 0.17) and HBI
or SCCAI scores 0.66 (n = 56, SE: 0.09, 95% CI: 0.49–0.83,
P = 0.08) (Figures 4B–D). The resulting combined calculated
probability had a maximum sensitivity of 90.7% and specificity of
68.4% in correctly discriminating IBD patients with low or high
endoscopic disease activity (Youden’s J statistic= 0.58).
In the CD subgroup, regarding the predictive value for
SES-CD scored endoscopic disease activity, serum levels of
SAA presented the best discriminative capacity as represented
by an AuROC of 0.79 (SE: 0.09, 95% CI: 0.61–0.96, P <
0.01) (Supplementary Figure 7). In the UC subgroup, the
combination of IL-6 and Eotaxin-1 demonstrated the best
predictive performance (AuROC 0.97, SE: 0.03, 95% CI: 0.92–
1.02, P < 0.001) (Supplementary Figure 8). Detailed subgroup
analyses for both CD and UC cohorts are described in
Supplementary Figures 7 and 8.
DISCUSSION
In this study, we demonstrate that serum Eotaxin-1, SAA, IL-
6, IL-8, IL-17A, and TNF-α are better predictors of endoscopic
disease activity in IBD than the routinely applied serum CRP,
fecal calprotectin levels and HBI or SCCAI scores. A combined
panel of Eotaxin-1, SAA, IL-6, and IL-8 showed the best
prediction of the actual mucosal status in IBDwith a sensitivity of
90.7% and specificity of 68.4%. Furthermore, only a few patients
were misclassified as having high endoscopic disease activity,
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FIGURE 2 | Distributions of serum concentrations of (A) Eotaxin-1, (B) serum amyloid A (SAA), (C) tumor necrosis factor alpha (TNF-α), (D) interleukin-6 (IL-6), (E)
interleukin-8 (IL-8) and (F) interleukin-17A (IL-17A), that were significantly different among binary ordered endoscopic disease activity, using a composite IBD
endoscopy score (0 or 1 indicating remission or mild disease and 2 or 3 indicating moderate or severe disease, respectively). *P < 0.05. **P < 0.01.
yielding a positive predictive value of 86.7%. The combination
of these four inflammatory biomarkers demonstrated higher
discriminative value regarding endoscopic disease activity in
IBD than routinely applied measures of disease activity (i.e.,
serum CRP, fecal calprotectin levels, and clinical disease
indices [HBI/SCCAI]).
All biomarkers that were found to be predictive for
endoscopically confirmed disease activity are involved in
the pathogenesis of IBD. Eotaxin-1 (CCL11) is a selective
chemoattractant and important in the activation and recruitment
of eosinophils to the lamina propria of the gut (29). Eotaxin-1
levels have been shown to be elevated in the serum of patients
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FIGURE 3 | Discriminative capacity of serum concentrations of (A) Eotaxin-1, (B) serum amyloid A (SAA), (C) tumor necrosis factor alpha (TNF-α), (D) interleukin-6
(IL-6), (E) interleukin-8 (IL-8), (F) interleukin-17A (IL-17A) regarding binary ordered endoscopic disease activity (remission (0) or mild (1) disease vs. moderate (2) or
severe (3) disease), as represented by the area under the receiver operating characteristics curve (AuROC). Of all individual molecules shown, Eotaxin-1 and SAA
display the best discriminative capacity regarding binary ordered endoscopic disease activity.
with (active) IBD (30–33). In our study, however, we found
higher serum Eotaxin-1 concentrations in UC as compared to
CD. Remarkably, serum levels were generally reduced in CD as
compared to healthy controls, though there was a large variation
in Eotaxin-1 levels in this patient group (Figure 1). Despite this,
we observed a clear positive correlation between inflammatory
activity in the composite IBD endoscopy score and serum
levels of Eotaxin-1 (Supplementary Figure 1). Moreover, serum
Eotaxin-1 showed discriminative value for differentiating IBD
patients having either remissive or mild disease from patients
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with moderate or severe endoscopic disease activity (Figure 3).
These findings of correlations between serum Eotaxin-1 levels
and disease activity corroborate previous observations in human
TABLE 3 | ROC analysis showing discriminative power of individual inflammatory
biomarkers that are significantly increased in IBD patients with moderate (2) or
severe (3) endoscopic disease activity as compared to patients with remission (0)
or mild (1) disease activity, as determined by the binary categorized, composite










Eotaxin-1 (ng/ml) 0.75 (0.62–0.87) 74.5/66.7% >0.21 ng/ml 0.41***
SAA (mg/l) 0.75 (0.62–0.87) 48.8/95.2% >17.5 mg/l 0.44**
TNF-α (pg/ml) 0.65 (0.52–0.78) 38.3/87.5% > 2.88 pg/ml 0.26*
IL-6 (pg/ml) 0.67 (0.53–0.81) 55.3/72.7% > 0.91 pg/ml 0.28*
IL-8 (pg/ml) 0.70 (0.58–0.83) 68.1/66.7% > 6.12 pg/ml 0.35**
IL-17A (pg/ml) 0.72 (0.57–0.86) 66.7/68.2% > 2.40 pg/ml 0.35**
Routine measures
CRP (mg/l) 0.57 (0.43–0.72) 51.1/66.7% > 5.73 mg/l 0.18
FC (µg/g) 0.66 (0.44–0.90) 80.1/50.0% > 735µg/g 0.32
HBI/SCCAI 0.66 (0.49–0.83) 62.9/64.3% > 6.5 points 0.27
*P-values were calculated for the difference between the area under the ROC curve
and the no-discrimination line (AuROC = 0.50). *P < 0.05 were considered statistically
significant. **P < 0.01. ***P < 0.001.
IBD and experimental colitis models that suggested that the
eosinophil-selective chemokine Eotaxin-1 associates with disease
pathogenesis (34, 35). Eotaxin-1 is produced by intestinal
epithelial cells, endothelial cells and macrophages under the
influence of several other cytokines that are involved in IBD
disease activity, such as IL-17A (36–39).
Serum amyloid A (SAA) was also predictive for IBD disease
activity. SAA is an apolipoprotein of high-density lipoproteins
(HDL) and belongs to the family of acute-phase reactants.
It is produced by the liver upon enhanced serum levels of
pro-inflammatory cytokines, such as TNF-α and IL-6, and
is enhanced in several chronic inflammatory diseases (40,
41). Previously, it was demonstrated that circulating IL-6 and
SAA are useful indicators of disease activity in IBD (42).
In contrast to the pro-inflammatory nature of most of the
studied cytokines, it is unknown whether SAA contributes to
inflammation. The positive correlation with disease activity
suggests a pro-inflammatory function, but recently it was also
shown that SAA may protect the epithelial barrier by stimulating
protective and anti-inflammatory IL-22-producing neutrophils
(43). Irrespective of its role in disease development, SAA has
been shown to be the most sensitive acute-phase protein in IBD
(when compared to other acute phase proteins, such as alpha-1-
antichymotrypsin (alpha-1-ACT) and alpha-1-acid glycoprotein
(alpha-1-AGP), or even CRP) (44). Therefore, SAA may be of
added value as inflammatory biomarker in monitoring the acute-
phase reaction, besides CRP (45).
FIGURE 4 | Areas under the receiver operating characteristics curve (AuROC) for (A) the best predictive combination of biomarkers (serum amyloid A (SAA),
interleukin-6 (IL-6), interleukin-8 (IL-8) and Eotaxin-1) (n = 64), (B) serum C-reactive protein (CRP) levels, (C) fecal calprotectin (FC) levels (µg/g) (n = 25) and (D)
Harvey Bradshaw Index (HBI) or Simple Clinical Colitis Activity Index (SCCAI) (n = 56).
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IL-6 was also part of the selected combination of predictive
inflammatory biomarkers. IL-6 is one of the most ubiquitously
present and pleiotropic cytokines that is involved in most
(chronic) inflammatory diseases, including IBD (46). IL-6 can
change the balance of effector CD4+ T-cell subsets. It is produced
by innate immune cells, such as macrophages, neutrophils and
mast cells, and forms a bridge between the innate and the
adaptive immune system. Upon acute inflammatory events, IL-
6 is recognized as important stimulator of acute-phase reactant
production in the liver, including CRP. In IBD, the importance
of IL-6 is highlighted by the fact that serum concentrations rise
concurrently with increasing inflammatory disease activity, as
well as elevated soluble receptor complexes (sIL-6R/IL-6) that
can bind to and activate IL-6R-lacking immune cells (trans
signaling), contributing to chronic mucosal inflammation (47).
Pro-inflammatory actions of IL-6 have been demonstrated to
predominantly occur via trans signaling, which is strongly
associated with the development of and sustainment of intestinal
inflammation in IBD (48–50). Here, IL-6 levels fairly accurately
differentiated between high and low endoscopic disease activity.
As a result, serum IL-6 levels made a substantial contribution to
the predictive power of the final biomarker combination.
IL-8 is known as an important neutrophil chemoattractant,
modulating recruitment, and degranulation of neutrophils
located in the intestinal mucosa (51). Previously, it was
demonstrated that serum IL-8 levels are elevated in active IBD,
most prominently in UC, as compared to healthy subjects (52).
In line, we found significantly elevated serum concentrations of
IL-8 in UC compared to CD and healthy controls. Therefore,
IL-8 is suggested to be a key factor in the process of neutrophil-
mediated intestinal inflammation in active UC. Previously, it
was shown that mucosal IL-8 levels can predict future disease
relapse in patients with quiescent UC (53). Moreover, serum IL-8
levels present high accuracy in differentiating IBD from irritable
bowel syndrome (IBS) patients (54). In this respect, IL-8 might be
particularly helpful in identifying an acute disease exacerbation,
irrespective of the often non-specific clinical presentation.
Currently, disease activity in IBD is clinically assessed by
evaluating a combination of symptoms (quantified with clinical
risk scoring methods), biochemical measures such as serum CRP
and fecal calprotectin, and ultimately endoscopic evaluation.
However, the clinical scoring methods, such as the Harvey
Bradshaw Index (HBI) or the Simple Clinical Colitis Activity
Index (SCCAI) correlate poorly with endoscopic disease activity
(24, 25, 55–57). Our results are in line with these studies,
since only serum IL-6 levels correlated significantly with the
clinical disease indices in our cohort. Moreover, associations
between serum CRP and fecal calprotectin and endoscopic
disease activity in IBD appear inconsistent (58). Despite this,
these parameters are the most frequently-used non-invasive
biomarkers analyzed to monitor disease activity in IBD (14,
23, 59). However, several studies have shown that one single
biomarker is unlikely to accurately predict the mucosal status
in IBD, given its complex immunological pathogenesis (10,
11, 14, 17, 60). Endoscopic remission is the ultimate goal
and measure of therapeutic efficacy in IBD. Additional non-
invasive markers are needed to be able to accurately represent
endoscopic remission (61, 62). Previous studies have developed
disease activity indices reflectingmucosal status, based on clinical
characteristics and standard laboratory measurements, but few
included inflammatory biomarkers as we investigated in this
study (63). Incorporation of such inflammatory biomarkers in
existing prediction models or disease indices may contribute
to establishing an immunology-based prediction model for
endoscopic mucosal status in IBD.
An important strength of the present study is the
comprehensive analysis of a selected panel of serum
inflammatory biomarkers using an electrochemiluminescence
(ECL) assay. Using this highly-sensitive, validated detection
method of serum inflammatory biomarkers, we were able to
establish serum biomarker concentrations with a broad dynamic
range of detection. However, biomarker concentrations were not
within the detection range in a small number of samples (6.0%)
and were excluded from the analyses. In order to determine
whether this may skew the interpretation of our results, we
performed a full statistical analysis on a dataset where missing
values were replaced by the lower limit of detection (LLoD)
or upper limit of detection (ULoD) as indicated by the signals
obtained in the ECL assay. Importantly, these analyses further
confirmed the final prediction model.
In an earlier study, we found correlations between several
serum inflammatory cytokines in CD and fecal calprotectin
levels, where we observed positive correlations for Th1- and
Th17- associated serum cytokines (including CRP, SAA, and
IL-6) and fecal calprotectin levels (22). However, that study
was limited by a relatively small cohort of CD patients and
the absence of endoscopic results, which prevented us from
establishing correlations with IBD disease activity. Likewise, the
current study has also some limitations. For instance, a larger
cohort would have allowed us to predict endoscopic disease
activity using the pre-defined categories as outcome parameter
with values ranging from 0 to 3. In this respect, the inclusion
of more IBD patients with endoscopic remission could have
enabled us to assess the predictive accuracy of a combination of
inflammatory biomarkers between the quiescent and active state
of the disease and establish clinically useful cut-offs. Similarly, a
greater sample size would have resulted inmore reliable subgroup
analyses for CD and UC. Moreover, this would have provided us
with the ability to reliably adjust for confounding variables (e.g.,
medication use, co-morbidity or acute inflammatory events).
Lastly, shortening of the time interval between endoscopy and
serum sample collection would have improved the reliability of
our results.
Our results demonstrate that a combination of serum
inflammatory biomarkers has the potential to differentiate
between IBD patients with varying degrees of endoscopic disease
activity in a minimally invasive manner. The panel of four
biomarkers described in this study has a high accuracy, and it
is important now to externally validate this combined array of
biomarkers in another IBD cohort. As such, the development
of a minimally invasive multi-marker serum test may be
particularly clinically relevant as the discrimination between
varying degrees of endoscopically active disease may help in
guiding therapeutic decision making and adjusting medical
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therapy (61). Furthermore, endoscopic remission or ‘mucosal
healing’ is increasingly recognized as important therapeutic
endpoint in clinical trials (64). Since prediction of endoscopic
disease activity may be found in a combined set of serum
biomarkers, this study is also aimed to trigger avenues for future
research that further evaluate the potential of a serum biomarker
panel to represent disease activity in IBD. Additionally, since
cytokines play a pivotal role in the immunopathogenesis of IBD,
it is interesting to analyze the effect of induction therapy on
serum inflammatory status in relation to endoscopic remission
in IBD. Future studies are warranted that focus on the diagnostic
potential of this distinct inflammatory biomarker profile in
predicting response to (biological) therapy in IBD.
In conclusion, the panel of four serum inflammatory
biomarkers identified in this study shows a predictive value
of endoscopic disease activity in IBD that is much better
than current routine laboratory tests. SAA, Eotaxin-1, IL-
6, IL-8, IL-17A, and TNF-α all individually showed better
predictive performances compared to CRP, fecal calprotectin
and HBI/SCCAI scores. The best prediction of luminal disease
activity was observed when SAA, IL-6, IL-8, and Eotaxin-1 were
combined, which, as a relatively small panel of biomarkers,
harbors great potential to improve monitoring of intestinal
inflammatory activity and therapeutic efficacy in IBD.
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